Posaconazole Tablet, Delayed Release
FDA Label NDC 51407-676

52 label sections · Submitted to the FDA by Golden State Medical Supply, Inc. · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Golden State Medical Supply, Inc. for the product Posaconazole (NDC 51407-676). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding recent major changes, 1.2 prophylaxis of invasive aspergillusand candidainfections, 2.1 important administration instructions, 2.2 recommended dosage of posaconazole delayed-release tablets in adult patients, 2.3 recommended dosage of posaconazole delayed-release tablets for the prophylaxis of invasive aspergillusand candidainfections in pediatric patients (ages 13 to less than 18 years of age), 2.7 administration instructions for posaconazole delayed-release tablets, 2.9 non-substitutability between noxafil ®oral suspension and other formulations, 2.11 dosage modifications in patients with renal impairment, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

Label Section Quick Index

* Please review the disclaimer below.